Evidence map›Paper›PMID 34457125›Full record

ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science

Heterogeneity in COVID-19 Patients at Multiple Levels of Granularity: From Biclusters to Clinical Interventions.

Suresh K Bhavnani, Erich Kummerfeld, Weibin Zhang, Yong-Fang Kuo, Nisha Garg, Shyam Visweswaran, Mukaila Raji, Ravi Radhakrishnan, Georgiy Golvoko, Sandra Hatch and 3 more

Abstract read
In one paragraph

Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Subtyping Social Determinants of Health inmedRxiv : the preprint server for health sciences · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Suresh K BhavnaniPreventive Medicine and Population Health.
Erich KummerfeldInst. for Health Informatics.
Weibin ZhangPreventive Medicine and Population Health.
Yong-Fang KuoPreventive Medicine and Population Health.
Nisha GargDepts. of Microbiology & Immunology and Pathology.
Shyam VisweswaranDept. of BMI, Univ. of Pittsburgh, Pittsburgh, PA.
Mukaila RajiDiv. of Geriatrics, Internal Medicine.
Ravi RadhakrishnanDepts. of Surgery & Pediatrics.
Georgiy GolvokoDepts. of Pharm. & Toxicology.
Sandra HatchCancer Center, Univ. of Texas Medical Branch, Galveston TX.
Michael UsherInst. for Health Informatics.
Genevieve Melton-MeauxInst. for Health Informatics.
Christopher TignanelliDept. of Surgery, Univ. of Minnesota, Minneapolis, MN.

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
UTMB OAIC Research Education Component (REC)P30AG024832 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI JAMES S. GOODWIN, MD, MELISSA M. MORROW · 2005 to 2026
$26.7M
UTMB Clinical and Translational Science AwardUL1TR000071 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$14.4M
NCATS NIH HHS UL1 TR000071NCATS NIH HHS UL1 TR002494NIA NIH HHS P30 AG024832
6 · The paper itself

Abstract

Several studies have shown that COVID-19 patients with prior comorbidities have a higher risk for adverse outcomes, resulting in a disproportionate impact on older adults and minorities that fit that profile. However, although there is considerable heterogeneity in the comorbidity profiles of these populations, not much is known about how prior comorbidities co-occur to form COVID-19 patient subgroups, and their implications for targeted care. Here we used bipartite networks to quantitatively and visually analyze heterogeneity in the comorbidity profiles of COVID-19 inpatients, based on electronic health records from 12 hospitals and 60 clinics in the greater Minneapolis region. This approach enabled the analysis and interpretation of heterogeneity at three levels of granularity (cohort, subgroup, and patient), each of which enabled clinicians to rapidly translate the results into the design of clinical interventions. We discuss future extensions of the multigranular heterogeneity framework, and conclude by exploring how the framework could be used to analyze other biomedical phenomena including symptom clusters and molecular phenotypes, with the goal of accelerating translation to targeted clinical care.

Indexed as

COVID-19AgedCohort StudiesComorbidityHumansPhenotypeSARS-CoV-2

Identifiers

PMID34457125
PMCPMC8378636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.